Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico
Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for controlling the coronavirus disease 2019 (COVID-19) pandemic worldwide. Antibody response is essential to understand the immune response to different viral targets after vaccination with diff...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.916241/full |
| _version_ | 1811288762178600960 |
|---|---|
| author | Henry Puerta-Guardo Henry Puerta-Guardo Manuel Parra-Cardeña Fernando Peña-Miranda Felipe Flores-Quintal Pilar Granja-Pérez Salha Villanueva-Jorge Refugio González-Losa Laura Conde-Ferraez Jesus Gómez-Carballo Gonzalo Vazquez-Prokopec James T. Earnest Pablo Manrique-Saide Guadalupe Ayora-Talavera |
| author_facet | Henry Puerta-Guardo Henry Puerta-Guardo Manuel Parra-Cardeña Fernando Peña-Miranda Felipe Flores-Quintal Pilar Granja-Pérez Salha Villanueva-Jorge Refugio González-Losa Laura Conde-Ferraez Jesus Gómez-Carballo Gonzalo Vazquez-Prokopec James T. Earnest Pablo Manrique-Saide Guadalupe Ayora-Talavera |
| author_sort | Henry Puerta-Guardo |
| collection | DOAJ |
| description | Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for controlling the coronavirus disease 2019 (COVID-19) pandemic worldwide. Antibody response is essential to understand the immune response to different viral targets after vaccination with different vaccine platforms. Thus, the main aim of this study was to describe how vaccination with two distinct SARS-CoV-2 vaccine preparations elicit IgG antibody specific responses against two antigenically relevant SARS-CoV-2 viral proteins: the receptor-binding domain (RBD) and the full-length spike (S). To do so, SARS-CoV-2 protein specific in-house enzyme-linked immunosorbent assays (ELISAs) were standardized and tested against serum samples collected from 89 adults, recipients of either a single-dose of the Spike-encoding mRNA-based Pfizer/BioNTech (Pf-BNT) (70%, 62/89) or the Spike-encoding-Adenovirus-5-based CanSino Biologics Inc. (CSBIO) (30%, 27/89) in Merida, Mexico. Overall, we identified an IgG seroconversion rate of 88% (68/78) in all vaccinees after more than 25 days post-vaccination (dpv). Anti-RBD IgG-specific responses ranged from 90% (46/51) in the Pf-BNT vaccine at 25 dpv to 74% (20/27) in the CSBIO vaccine at 42 dpv. Compared to the S, the RBD IgG reactivity was significantly higher in both Pf-BNT (p < 0.004) and CSBIO (p < 0.003) vaccinees. Interestingly, in more than 50% of vaccine recipients, with no history of COVID-19 infection, antibodies against the nucleocapsid (N) protein were detected. Thus, participants were grouped either as naïve or pre-exposed vaccinees. Seroconversion rates after 25 and more dpv varies between 100% in Pf-BNT (22/22) and 75% (9/12) in CSBIO pre-exposed vaccinees, and 89% (26/29) and 73% (11/15) in Pf-BNT and CSBIO naïve vaccine recipients, respectively. In summary, observed seroconversion rates varied depending on the type of vaccine, previous infection with SARS-CoV-2, and the target viral antigen. Our results indicate that both vaccine preparations can induce detectable levels of IgG against the RBD or Spike in both naïve and SARS-CoV-2 pre-exposed vaccinees. Our study provides valuable and novel information about the serodiagnosis and the antibody response to vaccines in Mexico. |
| first_indexed | 2024-04-13T03:42:53Z |
| format | Article |
| id | doaj.art-c20841f98aa54d3e980d32f829e77227 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T03:42:53Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-c20841f98aa54d3e980d32f829e772272022-12-22T03:04:06ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-07-01910.3389/fmed.2022.916241916241Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, MexicoHenry Puerta-Guardo0Henry Puerta-Guardo1Manuel Parra-Cardeña2Fernando Peña-Miranda3Felipe Flores-Quintal4Pilar Granja-Pérez5Salha Villanueva-Jorge6Refugio González-Losa7Laura Conde-Ferraez8Jesus Gómez-Carballo9Gonzalo Vazquez-Prokopec10James T. Earnest11Pablo Manrique-Saide12Guadalupe Ayora-Talavera13Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, MexicoUnidad Colaborativa para Bioensayos Entomológicos, Campus de Ciencias Biológicas y Agropecuarias, Universidad Autónoma de Yucatán, Mérida, MexicoCentro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, MexicoLaboratorio Estatal de Salud Pública, Servicios de Salud de Yucatán, Mérida, MexicoLaboratorio Estatal de Salud Pública, Servicios de Salud de Yucatán, Mérida, MexicoLaboratorio Estatal de Salud Pública, Servicios de Salud de Yucatán, Mérida, MexicoLaboratorio Estatal de Salud Pública, Servicios de Salud de Yucatán, Mérida, MexicoCentro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, MexicoCentro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, MexicoCentro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, MexicoDepartment of Environmental Sciences, Emory University, Atlanta, GA, United StatesDepartment of Environmental Sciences, Emory University, Atlanta, GA, United StatesUnidad Colaborativa para Bioensayos Entomológicos, Campus de Ciencias Biológicas y Agropecuarias, Universidad Autónoma de Yucatán, Mérida, MexicoCentro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, MexicoSeveral vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for controlling the coronavirus disease 2019 (COVID-19) pandemic worldwide. Antibody response is essential to understand the immune response to different viral targets after vaccination with different vaccine platforms. Thus, the main aim of this study was to describe how vaccination with two distinct SARS-CoV-2 vaccine preparations elicit IgG antibody specific responses against two antigenically relevant SARS-CoV-2 viral proteins: the receptor-binding domain (RBD) and the full-length spike (S). To do so, SARS-CoV-2 protein specific in-house enzyme-linked immunosorbent assays (ELISAs) were standardized and tested against serum samples collected from 89 adults, recipients of either a single-dose of the Spike-encoding mRNA-based Pfizer/BioNTech (Pf-BNT) (70%, 62/89) or the Spike-encoding-Adenovirus-5-based CanSino Biologics Inc. (CSBIO) (30%, 27/89) in Merida, Mexico. Overall, we identified an IgG seroconversion rate of 88% (68/78) in all vaccinees after more than 25 days post-vaccination (dpv). Anti-RBD IgG-specific responses ranged from 90% (46/51) in the Pf-BNT vaccine at 25 dpv to 74% (20/27) in the CSBIO vaccine at 42 dpv. Compared to the S, the RBD IgG reactivity was significantly higher in both Pf-BNT (p < 0.004) and CSBIO (p < 0.003) vaccinees. Interestingly, in more than 50% of vaccine recipients, with no history of COVID-19 infection, antibodies against the nucleocapsid (N) protein were detected. Thus, participants were grouped either as naïve or pre-exposed vaccinees. Seroconversion rates after 25 and more dpv varies between 100% in Pf-BNT (22/22) and 75% (9/12) in CSBIO pre-exposed vaccinees, and 89% (26/29) and 73% (11/15) in Pf-BNT and CSBIO naïve vaccine recipients, respectively. In summary, observed seroconversion rates varied depending on the type of vaccine, previous infection with SARS-CoV-2, and the target viral antigen. Our results indicate that both vaccine preparations can induce detectable levels of IgG against the RBD or Spike in both naïve and SARS-CoV-2 pre-exposed vaccinees. Our study provides valuable and novel information about the serodiagnosis and the antibody response to vaccines in Mexico.https://www.frontiersin.org/articles/10.3389/fmed.2022.916241/fullSARS-CoV-2 antigensvaccineesIgG responsePfizerCanSino |
| spellingShingle | Henry Puerta-Guardo Henry Puerta-Guardo Manuel Parra-Cardeña Fernando Peña-Miranda Felipe Flores-Quintal Pilar Granja-Pérez Salha Villanueva-Jorge Refugio González-Losa Laura Conde-Ferraez Jesus Gómez-Carballo Gonzalo Vazquez-Prokopec James T. Earnest Pablo Manrique-Saide Guadalupe Ayora-Talavera Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico Frontiers in Medicine SARS-CoV-2 antigens vaccinees IgG response Pfizer CanSino |
| title | Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico |
| title_full | Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico |
| title_fullStr | Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico |
| title_full_unstemmed | Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico |
| title_short | Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico |
| title_sort | human igg antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor binding domain spike and nucleocapsid in vaccinated adults from merida mexico |
| topic | SARS-CoV-2 antigens vaccinees IgG response Pfizer CanSino |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.916241/full |
| work_keys_str_mv | AT henrypuertaguardo humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT henrypuertaguardo humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT manuelparracardena humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT fernandopenamiranda humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT felipefloresquintal humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT pilargranjaperez humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT salhavillanuevajorge humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT refugiogonzalezlosa humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT lauracondeferraez humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT jesusgomezcarballo humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT gonzalovazquezprokopec humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT jamestearnest humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT pablomanriquesaide humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico AT guadalupeayoratalavera humaniggantibodyresponsestosevereacuterespiratorysyndromecoronavirus2viralantigensreceptorbindingdomainspikeandnucleocapsidinvaccinatedadultsfrommeridamexico |